News
CMND
1.200
+3.45%
0.040
Weekly Report: what happened at CMND last week (0422-0426)?
Weekly Report · 9h ago
Weekly Report: what happened at CMND last week (0415-0419)?
Weekly Report · 04/22 11:14
Psychedelics Headlines: Dementia Prevention, Psychological Flexibility, Ancient Romans' Trips And More
Benzinga's psychedelic headlines roundup includes a look at the first two weeks of April 2024. Psilocybin could alter mechanisms associated with major depression and neurodegenerative diseases. Ancient Romans used to trip on hallucinogenic plants, archeologists say. Psycon's 2024 edition will take place in Colorado in May.
Benzinga · 04/17 13:13
Clearmind signs agreement for psychedelic compounds for mental disorders treatment
Seeking Alpha · 04/17 12:59
Psyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna & More
DEA Revisits Proposed Ban On Two Psychedelic Compounds: Researchers Disagree, Insist on Hearings. The Drug Enforcement Administration is revisiting its stance on the classification of two psychedelic compounds. The agency has proposed both be listed as Schedule I substances with no recognized medical use. Benzinga Psychedelics Podcast features an expert on the ancient healing plant kanna.
Benzinga · 04/17 12:42
CLEARMIND MEDICINE ANNOUNCES EXCLUSIVE LICENSING AGREEMENT FOR GENERATION 3.0 PSYCHEDELIC COMPOUNDS FOR THE TREATMENT OF MENTAL DISORDERS
Reuters · 04/17 11:49
Weekly Report: what happened at CMND last week (0408-0412)?
Weekly Report · 04/15 11:06
CLEARMIND MEDICINE FILES U.S. PATENT APPLICATION FOR PSYCHEDELIC-BASED TREATMENT FOR EATING DISORDERS
Reuters · 04/10 11:17
Clearmind Medicine CEO Issues Letter to Shareholders
Clearmind Medicine Inc. Is a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics. The Company's CEO, Dr. Adi Zuloff-Shani, sent a letter to shareholders. Clearmind is a company that aims to solve major under-treated health problems.
Barchart · 04/09 07:07
Weekly Report: what happened at CMND last week (0401-0405)?
Weekly Report · 04/08 11:11
Weekly Report: what happened at CMND last week (0325-0329)?
Weekly Report · 04/01 11:09
Psychedelics Headlines: A Form Of Life, Treating Chronic Pain, Microdosing And More
Benzinga's psychedelic headlines roundup includes news from the last two weeks of March 2024. Psychedelic therapy as a form of life and the role of psychedelics in the management of chronic pain are among the topics. A new study shows psilocybin is a prodrug of psilocin. Frank Herbert’s magic mushrooms are available in Canada.
Benzinga · 03/30 12:57
Psyched: 5-MeO-DMT For Depression, Utah Hospitals Providing Therapy, Elon Musk And Meta's Influence
Utah hospitals will soon provide psilocybin and MDMA therapy for mental health conditions in a pilot program. Beckley Psytech and atai announce positive initial results from a clinical trial of 5-MeO-DMT in Treatment Resistant Depression. Prosecutors in Virginia are probing whether Facebook's social media platforms are facilitating the illegal sale of drugs. Elon Musk makes the case for using psychedelics in a new episode of the Benzinga Psychedelics Podcast.
Benzinga · 03/29 16:43
BRIEF-Clearmind Medicine Announces International Patent Application For Preventing, Treating Depression
Reuters · 03/27 13:12
Weekly Report: what happened at CMND last week (0318-0322)?
Weekly Report · 03/25 11:12
Psyched: LSD, Psilocybin As Breakthrough Therapies, $14M Fed Grant For Ibogaine, Indiana's Research And More
FDA Grants Cybin Breakthrough Therapy Status For Major Depression Psilocybin Therapy, Company Announces Positive Clinical Data & Canadian $150M Private Placement. Psychedelics biopharma company Cybin Inc. Announced that the FDA has granted it a breakthrough therapy designation for its LSD-based treatment for anxiety disorder. The company also announced the pricing of an underwritten offering of $175 million in shares.
Benzinga · 03/20 18:49
Why Taysha Gene Therapies Shares Are Trading Higher By Around 27%; Here Are 20 Stocks Moving Premarket
Shares of Taysha Gene Therapies, Inc. Rose sharply in today's pre-market trading after the company reported a year-over-year increase in FY23 EPS results. ETAO International Co., Ltd. Shares rose 200.4% to $0.4296 in pre- market trading. Getty Images Holdings, Inc., and Canopy Growth Corp. Were among the other stocks moving in the day's trading.
Benzinga · 03/20 12:20
EURN, STI and PUK among pre-market losers
On the Move EURN, STI and PUK among pre-market losers. Aquestive Therapeutics (AQST) -13% on prices $75M offering. Euronav NV (EURN) -7% after Q4 earnings release.
Seeking Alpha · 03/20 12:11
Clearmind Medicine's Psychedelic Treatment Bags Divisional Patent Approval in China
Benzinga · 03/19 11:56
Breakthrough in Wellness: Clearmind Medicine's Psychedelic Treatment Granted Divisional Patent Approval in China
A Novel Approach to Combatting Binge Behaviors with Groundbreaking Psychedelic Therapy. Clearmind Medicine Inc. Granted divisional patent approval by the China National Intellectual Property Administration. The company is a biotech company focused on development of novel psychedelic-derived therapeutics.
Barchart · 03/19 06:55
More
Webull provides a variety of real-time CMND stock news. You can receive the latest news about Clearmind Medici through multiple platforms. This information may help you make smarter investment decisions.
About CMND
Clearmind Medicine Inc. is a psychedelic pharmaceutical biotech company. The Company is focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorders. The Company researches and develops psychedelic-based compounds and attempts to commercialize them as regulated medicines, foods, or supplements. The Company’s intellectual portfolio consists of 15 patent families, including 27 granted patents and 24 pending applications. The portfolio spans a range of jurisdictions, including the United States, Europe, India, and China.